

NO POSTAGE
NECESSARY
IF MAILED
IN THE
UNITED STATES

BUSINESS REPLY MAIL
FIRST-CLASS MAIL PERMIT NO 1316 WASHINGTON DC

POSTAGE WILL BE PAID BY NATIONAL INSTITUTES OF HEALTH

ETIB NCI NIH
ATTN: KATE CASTRO
10 CENTER DR RM 12S226 MSC 1907
BETHESDA MD 20814-9692

EXPERIMENTAL TRANSPLANTATION
AND IMMUNOLOGY BRANCH, NCI, NIH
BLDG 10, RM 12S226 MSC 1907
10 CENTER DR
BETHESDA MD 20892-1907

OFFICIAL BUSINESS
PENALTY FOR PRIVATE USE $300

Other Services

Chronic Graft-Versus-Host Disease Clinic:

This multidisciplinary team serves as a model for cGVHD patient care and promotes interdisciplinary clinical research. Through collaboration among a facet of health care professionals representing medical and pediatric oncology, rehabilitation medicine, rheumatology, gynecology, infectious disease, palliative care, ophthalmology, dermatology, dentistry, oral medicine, oral surgery, nutritional support, social work, oncology nursing, and clinic pain research, we are able to provide patients an array of therapeutic alternatives to a complex condition that is clinically challenging with little progress in therapy.

Consultation Services:

We are pleased to offer consultative services to you and your patients in order to discuss and provide recommendations on all available treatment options, including non-transplantation options, within and outside the Experimental Transplantation and Immunology Branch as well as within and outside the National Cancer Institute.

Program Information:

If you are interested in any specific protocol(s), services, or the program in general, please feel free to contact any of the investigators listed directly or you may contact our transplant coordinator listed on back. Thank you. We look forward to working with you and your patients.

Please contact our Team Coordinator:

Kate Castro
301-435-5942
castrok@mail.nih.gov

9000 Rockville Pike
Building 10, Room 12N226
Bethesda, MD 20892

Web site:
http://bethesdatrials.nci.nih.gov
Fax: 301-435-6830

Clinical Studies Support Center:
1-888-NCI 1937

NIH Publication No. 04-5602
October 2004

Clinical Trials in Hematopoietic Stem Cell Transplantation and Immunology

Experimental Transplantation
and Immunology Branch
Center for Cancer Research
NATIONAL CANCER INSTITUTE

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Mission

The Experimental Transplantation and Immunology Branch is dedicated to coordinated efforts in basic, preclinical and clinical investigations in the areas of immunology, tumor angiogenesis, hematopoiesis, and hematopoietic stem cell transplantation. The goal is to generate information from basic and preclinical investigations leading to the development of curative hematopoietic stem cell transplant-based therapies. Information from treatment protocols (including novel endpoints generated in the course of basic/preclinical research) is used to generate new questions and studies in the basic and preclinical research efforts.

The Research Team

Michael Bishop, M.D.
Clinical Head and Investigator
NCI Experimental Transplantation
and Immunology Branch
Phone: 301-435-2764
Fax: 301-480-4354
Email: mbishop@mail.nih.gov

Daniel Fowler, M.D.
Clinical Investigator
T Cell and Allograft Engineering
Phone: 301-435-8641
Fax: 301-480-4354
Email: dhfowler@helix.nih.gov

Claude Kasten-Sportes, M.D.
Staff Clinician
Immune Reconstitution in Cancer Vaccines
Phone: 301-435-5280
Fax: 301-402-7515
Email: kastensc@mail.nih.gov

Steven Pavletic, M.D., M.S., F.A.C.P.
Head
Graft-Versus-Host and Autoimmunity Unit
Phone: 301-402-4899
Fax: 301-480-4354
Email: pavletis@mail.nih.gov

Juan Gea-Banacloche, M.D.
Staff Clinician
Infectious Diseases
Phone: 301-435-2326
Fax: 301-402-7515
Email: banacloj@mail.nih.gov

Study Details

Confidentiality: Under Federal law, NCI cannot reveal any information that is collected from study participants to anyone other than persons directly involved with the study. No personal identifying information will be released or published. Access to your personal records is not allowed without your written consent.

Costs: All study-related medical expenses are paid by the NCI. Once participants are found eligible, NCI may be able to assist with travel costs and with daily vouchers.

Collaboration: Study participants will remain in collaborative care with their primary physicians while participants on our research protocols. All treatment options will be discussed with participants and the respective home practitioners. The NCI will also provide assistance in establishing care with appropriate physicians as needed.

Areas of Clinical Research

Lymphoma and other Hematologic Malignancies

- Pilot Study of Rapamycin Generated Donor Th2 Cells and In Vivo Rapamycin for GVHD Prevention after Allogeneic HSCT for Hematologic Malignancy, Protocol # 04-C-0055
- T-Cell Depleted, Reduce-Intensity Allogeneic Stem Cell Transplantation from Haploidentical related Donors for Hematologic Malignancies, Protocol # 04-C-0116
- Active Immunization of Sibling Stem Cell Transplant Donors Against Purified Myeloma Protein of the Stem Cell Recipient with Multiple Myeloma in the Setting of Non-Myeloblative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation, Protocol # 00-C-0201

Graft-Versus-Host Disease and Auto-Immune Diseases

- A Pilot Study of Intensified Lyphodepletion followed by Autologous Hematopoietic Stem Cell Transplantation in Patients with Severe Systemic Lupus Erythematous, Protocol # 04-C-0095

Breast Cancer and Other Solid Tumors

- Allogeneic Breast Protocol 2: Phase I Trial of T-Cell Exchange with Th2/Tc2 for Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for Metastatic Breast Cancer, Protocol # 04-C-0131
- A Phase I-II Study of Tumor Vaccine following Chemotherapy in Patients with Previously Untreated Metastatic Breast Cancer: Vaccine-Induced Bias of T-Cell Repertoire Reconstitution After T-Cell Re-Infusion, Protocol # 03-C-0040
- A Pilot Study of Paclitaxel / Cyclophosphamide and High-dose Melphalan / Etoposide with Autologous Progenitor Cell Transplantation for the Treatment of Inflammatory Breast Cancer, Protocol # 96-C-0104
- Phase I Study of Subcutaneous "CYT 99 007" (Interleukin 7) in Patients with Refractory Non-Hematologic Malignancy, Protocol # 03-C-0152

Experimental Transplantation and Immunology Branch

CENTER FOR CANCER RESEARCH

NATIONAL CANCER INSTITUTE

For more information regarding the Experimental and Transplantation and Immunology Branch, please advise us on your interest:

☐ Yes, I would like a member of your branch to present treatment options to our providers.

☐ Please send detailed summaries of areas of clinical research which includes: Primary and Secondary Objectives, Precis, Eligibility Assessment and Enrollment, and Study Design.

☐ Yes, please feel free to contact me with updates of treatment options available to my patients.

Organization _____

Contact Name _____

Title _____

Address _____

_____

_____

Phone _____

Fax _____

Email _____

Thank you. We look forward to working with you and your patients.